Our data plainly need confirmation in larger prospective trials, but given the poor prognosis linked to AMR we think it is important to highlight this serious long-term problem for more rigorous prospective investigations in the future. Until those data are obtainable, the conversion from a CNI-based therapy to an everolimusbased therapy needs to be carefully
(Read More…)
A phase III study revealed that this systemic therapy with fotemustine enhances the response and prolongs survival in comparison with dacarbazine in disseminated cutaneous malignant melanoma. However, the overall response rate remains small. We therefore wanted to find out whether conjunctival melanoma cells are sensitive to fotemustine. Imatinib (Gleevec) (Novartis, Basel, Switzerland) blocks competitively together
(Read More…)
The prevalence of ErbB2 amplification with breast cancer has led to the heavy pursuit of ErbB2 for a therapeutic target. Although both ErbB2 monoclonal antibody trastuzumab and ErbB1/ErbB2 dual kinase inhibitor, lapatinib, get met with success within the clinic many patients don’t benefit. Additionally, the most patients who initially reply will unfortunately ultimately advancement on
(Read More…)
Follow @selleckchem on twitter.
